CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 427 resultados LastUpdate Última actualización 03/10/2022 [12:06:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



previousPage Página2 de 18 nextPage   por página


USE OF A PHOSPHOLIPID EMULSION OF DIHYDROQUERCETIN IN THE CASE OF INFLAMMATORY RESPIRATORY DISEASES

NºPublicación: WO2022203546A1 29/09/2022

Solicitante:

FLAMENA LLC [RU]

RU_2757360_PA

Resumen de: WO2022203546A1

The invention relates to medicine, and more particularly to pulmonology. For treating inflammatory respiratory diseases, inter alia COVID-19 coronavirus disease, the use of a phospholipid emulsion containing an effective amount of dihydroquercetin, lecithin and glycine is proposed. The emulsion is taken by the patient 3-4 times a day, 15-30 minutes before meals, in an amount of 15-30 ml per dose for a period of 3-14 days. Use of this phospholipid emulsion makes it possible to effectively inhibit the symptoms of inflammatory respiratory diseases, normalize the patient's condition and reduce the risks of complications and deterioration of health in the case of the given pathology.

traducir

Anti-coronavirus antibodies and methods of use

NºPublicación: AU2020435452A1 29/09/2022

Solicitante:

ABCELLERA BIOLOGICS INC
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY

AU_2021234242_PA

Resumen de: AU2020435452A1

Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

traducir

BIOMARKER FOR ASSESSING THE RISK OF DEVELOPING ACUTE COVID-19 AND POST-ACUTE COVID-19

NºPublicación: US2022308056A1 29/09/2022

Solicitante:

OMEROS CORP [US]

WO_2022170090_A1

Resumen de: US2022308056A1

Disclosed herein are compositions, kits and methods for determining the concentration of fluid-phase MASP-2/C1-INH complex in a biological fluid, such as a biological fluid obtained from a subject infected with SARS-CoV-2. Also disclosed are methods of using said compositions, methods and kits for detection of MASP-2/C1-INH complex to determine the status of lectin pathway activation in a mammalian subject and thereby assess the risk of a subject that is or has been infected with SARS-CoV-2 for developing COVID-19-related ARDS or other poor outcome, or determine the need for treatment or efficacy of treatment of a subject in need thereof with a complement inhibitor such as a MASP-2 inhibitory agent.

traducir

PROBES COMPRISING METAL NANOPARTICLES, MAGNETIC NANOPARTICLES AND TARGET-SPECIFIC FLUOROPHORES OR BINDING SITES

NºPublicación: US2022308047A1 29/09/2022

Solicitante:

UNIV OREGON STATE [US]

Resumen de: US2022308047A1

Disclosed probes comprise metal nanoparticle cores associated with magnetic particles that allow probes associated with targets to be concentrated by an applied magnetic field to increase detection sensitivity and provide sufficient spacing between concentrated probes to avoid signal quenching. The probe may comprise at least one recognition receptor, and may further comprise at least one reporter molecule, such as a fluorescent tag, a Raman reporter, or combinations thereof. Concentrating probe-target composites substantially enhances a sensing signal, such as from 5 to 10 times, compared to detection without concentrating the probes. The method may be used to detect, for example, interleukins at concentrations at least as low as 25 pg/ml in sputum or blood from a subject for early and precise profiling of viral infections, such as SARS-CoV-2 infections.

traducir

Deuterated Angiotensin-Converting Enzyme-2 (ACE-2) Inhibitors

NºPublicación: US2022306646A1 29/09/2022

Solicitante:

DHANOA DALJIT SINGH [US]

Resumen de: US2022306646A1

The present invention is concerned with novel deuterated Angiotensin-Converting Enzyme-2 (ACE-2) inhibitors of general structural formula I, their optically active enantiomers and diastereoisomers, and pharmaceutical salts and compositions thereof, as well as combination therapies which include compounds of the present invention,These compounds have high potency and selectivity for Angiotensin-Converting Enzyme-2 (ACE-2) inhibition, and are useful in the treatment of infectious respiratory diseases including the pandemic disease Covid-19, Severe Acute Respiratory Syndrome (SARS-CoV-2), Severe Acute Respiratory Syndrome (SARS-CoV), and other diseases caused by coronaviruses.

traducir

MEDICAMENT AND FOOD FOR PREVENTING OR TREATING NOVEL CORONAVIRUS PNEUMONIA COVID-19 AND USE THEREOF

NºPublicación: US2022305092A1 29/09/2022

Solicitante:

GUANGZHOU CENTURY CLINICAL RES CO LTD [CN]
GUANGZHOU XIN CHUANGYI BIOPHARMACEUTICAL CO LTD [CN]
GUANGZHOU WELMAN NEW DRUG R&D CO LTD [CN]
XIANGBEI WELMAN PHARM CO LTD [CN]
NANJING KANGFUSHUN PHARMACEUTICAL CO LTD [CN]

Resumen de: US2022305092A1

The use of lysozyme or combinations comprising the lysozyme in preparing a medicament for preventing or treating the novel coronavirus pneumonia COVID-19 and in preparing a food for assisting in preventing or treating the novel coronavirus pneumonia COVID-19 is disclosed. The lysozyme or the combination of the lysozyme, as provided by the present invention, can effectively inhibit cell damage caused by the novel coronavirus, inhibit the inflammatory factors expression induced by the novel coronavirus, ameliorate airway obstruction and decreased expiratory volume caused by lung lesions, and ameliorate intestinal barrier dysfunction. The lysozyme or the combination of the lysozyme has good effects on patients with high viral load, respiratory distress, impaired intestinal function, etc., and can reduce the novel coronavirus infection rate and the incidence rate of severe novel coronavirus pneumonia.

traducir

Chlorophyllin Containing Pharmaceutical Composition For Prevention Of Pathogenesis Of Coronavirus Disease

NºPublicación: US2022305023A1 29/09/2022

Solicitante:

THE SEC DEP OF ATOMIC ENERGY [IN]

Resumen de: US2022305023A1

Pharmaceutical composition comprises of Chlorophyllin or salts thereof and its utilities including method of treatment, enabling the absorption of Copper-isochlorin e4 into human blood that results in an increase in lymphocyte count and decrease in the abundance of hematopoietic stem and progenitor cells (HPSCs) in human blood. The invention is directed to the treatment of conditions including corona-virus infection, immunosuppression, leucopenia and lymphopenia. The composition disclosed in the invention is thus useful for the treatment of corona virus disease caused by SARS-CoV-2 infection by decreasing viral infection, reducing cytokine storm and pro-inflammatory chemokines, reducing epithelial-cell oxidative-stress in the lungs and increasing the production of leukocytes.

traducir

IMMUNOBIOLOGICAL AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2

NºPublicación: US2022305111A1 29/09/2022

Solicitante:

FEDERAL STATE BUDGETARY INSTITUTION NATIONAL RES CENTER FOR EPIDEMIOLOGY AND MICROBIOLOGY [RU]

CN_115052624_PA

Resumen de: US2022305111A1

The invention relates to biotechnology, immunology and virology and, in particular, to an immunobiological agent for the prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2. Also, a method of inducing specific immunity to the SARS-CoV-2 virus is disclosed, comprising the administration to mammals of one or more immunobiological agents for the prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2. The invention facilitates an effective induction of the immune response to the SARS-CoV-2 virus.

traducir

MASSIVELY PARALLEL COVID-19 DIAGNOSTIC ASSAY FOR SIMULTANEOUS TESTING OF 19200 PATIENT SAMPLES

NºPublicación: US2022307095A1 29/09/2022

Solicitante:

PENN STATE RES FOUND [US]

Resumen de: US2022307095A1

The present disclosure provides methods and systems for the massively-parallel detection of pathogens, such as SARS-CoV-2 virus, in a set of multiple samples via PCR test. Various implementations may provide for barcode/primer sequences that are designed to allow for a large number of samples and/or multiple pathogens to be analyzed in a single test. Included within the scope hereof are methods and systems for performing tests of multiple samples at once, via a one-pot test protocol, as well as methods and systems for designing test parameters (such as barcode/primer sequences) in a manner that allows for parallel testing.

traducir

METHOD FOR THE TREATMENT OF COVID-19 INFECTIONS WITH PALMITOYLETHANOLAMIDE

NºPublicación: US2022304956A1 29/09/2022

Solicitante:

EPITECH GROUP S P A [IT]

Resumen de: US2022304956A1

The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

traducir

TREATMENT OF LONG HAULERS SYNDROME WITH NICLOSAMIDE

NºPublicación: US2022304959A1 29/09/2022

Solicitante:

FIRST WAVE BIOPHARMA [US]

Resumen de: US2022304959A1

Disclosed in certain embodiments is a method of treating long-haulers syndrome associated with infection (e.g., Covid-19) comprising administering a therapeutically effective amount of niclosamide or a pharmaceutically acceptable salt thereof to a patient in need thereof.

traducir

COMPOSITIONS AND METHODS FOR DIAGNOSING VIRAL INFECTIONS INCLUDING COVID-19 AND FOR INFECTION SEVERITY MONITORING AS WELL AS TARGETED DETECTION OF CYTOKINE STORM

NºPublicación: US2022305145A1 29/09/2022

Solicitante:

VYRIPHARM ENTPR INC [US]

Resumen de: US2022305145A1

Compositions and methods for the diagnosis and treatment of infectious diseases, including for the diagnosis and treatment of Cytokine Storm and Cytokine Release Syndrome. The compositions may include a conjugate of a nucleoside analog, a chelator, and a label for use as imaging and therapeutic agents.

traducir

COMPOSITIONS AND METHODS FOR INHIBITING PROTEOLYTIC ACTIVATION OF VIRUSES

NºPublicación: US2022304947A1 29/09/2022

Solicitante:

MAJEED MUHAMMED [IN]
NAGABHUSHANAM KALYANAM [US]
MUNDKUR LAKSHMI [IN]

Resumen de: US2022304947A1

The present invention discloses use of a composition comprising enriched in bisdemethoxycurcumin, specifically a composition comprising not less than 20% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% curcumin in preventing the activation of viral spike proteins by inhibiting the activity of proteolytic enzymes and in inhibiting the replication and growth of pathogenic viruses, specifically SARS-CoV-2 in mammalian cells. The invention also discloses the potential of the above composition in managing SARS-CoV-2 induced infections.

traducir

METHOD FOR THE TREATMENT OF COVID-19 INFECTIONS WITH PALMITOYLETHANOLAMIDE

NºPublicación: US2022304954A1 29/09/2022

Solicitante:

EPITECH GROUP S P A [IT]

Resumen de: US2022304954A1

The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

traducir

METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING A DISEASE OR A CONDITION

NºPublicación: WO2022201168A1 29/09/2022

Solicitante:

DEAD SEA MEDICA LTD [IL]

Resumen de: WO2022201168A1

The invention relates to a method and a composition for treating or preventing an inflammatory, autoimmune and/or Coronavirus disease and/or symptom. In some embodiments, the -invention relates to a method or a composition for treating or preventing a Coronavirus disease- 19 (COVID-19) as well as preventing and curing long term COVID-19 side effects. The composition is a herbal mineral composition or includes the active ingredients that may be found in herbs together with a mineral.

traducir

USE OF ACTIVE SUBSTANCES OF PLANT ORIGIN FOR THE TREATMENT OF COVID-19

NºPublicación: WO2022200352A1 29/09/2022

Solicitante:

UNIV DUISBURG ESSEN [DE]

DE_102021107070_PA

Resumen de: WO2022200352A1

The invention relates to the use of a compound according to formulae (1), (2) and/or (3) of the pharmaceutically acceptable salts or esters thereof for the preparation of a medicament for the prophylactic and/or therapeutic treatment of an infection with coronaviruses, in particular SARS-CoV-2.

traducir

USE OF PANTETHINE FOR THE TREATMENT OF SARS COV-2 INFECTIONS

NºPublicación: WO2022200468A1 29/09/2022

Solicitante:

INST NAT SANTE RECH MED [FR]
CENTRE NAT RECH SCIENT [FR]
UNIV PARIS CITE [FR]
LEBANESE UNIV [LB]

Resumen de: WO2022200468A1

SARS-CoV and SARS-CoV-2 share similar pathogenic pathways that interact with pathways of cellular cholesterol metabolism. Depletion of cholesterol from cell membranes reduced the infectivity of SARS-CoV by 90%. Several studies reported that pantethine was able to reduce total cholesterol levels and total fatty acids synthesis but its anti-SARS CoV-2 activity has never been investigated. The inventors now demonstrate that pantethine is highly effective in the control of SARS-CoV-2 infections in vitro. In particular, the inventors show that the effect of pathethine on the inhibition of the replication of SARS-CoV-2 is interested at the dose of 100 μM (inhibition is around 76%) and the most effective concentration is 1000 μM (inhibition is around 98%). Pantethine treatments were able to reduce significantly the expression of the viral Spike and Nucleocapsid proteins and the accessory proteins ORF6. Thus the present invention relates to the use of pantethine for the treatment of a SARS CoV-2 infection.

traducir

NOVEL USE OF AN IMMUNOGENIC OR VACCINAL COMPOSITION AGAINST COVID-19

NºPublicación: WO2022200384A1 29/09/2022

Solicitante:

EYE VACC [BE]

Resumen de: WO2022200384A1

The present invention relates to an anti-SARS-CoV-2 immunogenic or vaccinal composition for use in the treatment of COVID-19, the composition being characterised in that it is administered to the ocular mucosa and/or the urogenital mucosa.

traducir

HUMAN NEUTRALIZING ANTIGEN SPECIFIC PROTEINS FOR SPIKE-RBD OF SARS-COV-2

NºPublicación: WO2022200291A2 29/09/2022

Solicitante:

CEINGE BIOTECNOLOGIE AVANZATE SCARL [IT]

EP_4063384_A1

Resumen de: WO2022200291A2

The invention concerns antigen specific proteins, in particular antibodies or fragments thereof, specifically binding to RBD domain and interfering in the interaction of Spike protein with ACE2 receptor, said antigen specific proteins having neutralizing activity for infection of SARS-CoV2 virus and its derived variants.

traducir

COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19

NºPublicación: WO2022200086A1 29/09/2022

Solicitante:

SZEKERES THOMAS [AT]
JAEGER WALTER [AT]

Resumen de: WO2022200086A1

The invention discloses a compound with the general formula (I) wherein R1 to R6 are identical or not and are H, OH-, or OR7, wherein R7 is a C1 to C3 alkyl group or a C1 to C4 acyl group, with the proviso that at least four of R1 to R6 are different than H, for use in the treatment and prevention of COVID-19 in a human subject, especially for inhibiting SARS-CoV-2.

traducir

ANTIBODIES BINDING TO O-LINKED CARBOHYDRATES ON SARS-COV-2 SPIKE PROTEIN AND USES THEREOF

NºPublicación: WO2022198314A1 29/09/2022

Solicitante:

KORANEX CAPITAL [CA]

Resumen de: WO2022198314A1

A protein complex comprising a SARS-CoV-2 S protein or fragment thereof, expressing one or more carbohydrate antigens, bound to a recombinant ligand having binding specificity for said carbohydrate antigen, is described herein. The carbohydrate antigen may be an O-linked carbohydrate antigen, such as unsialylated Thomsen-Friedenreich (TF) antigen, sialylated TF antigen, unsialylated Tn antigen, sialylated Tn antigen, or any combination thereof. The ligand may be a recombinant antibody or an antigen-binding fragment thereof. Also described herein is the use of such a recombinant ligand for binding to a SARS-CoV-2 S protein or fragment thereof, for treating or reducing the risk of SARS-CoV-2 viral infection in a subject.

traducir

KIT FOR DETECTING NOVEL CORONAVIRUS, AND PREPARATION METHOD THEREFOR AND DETECTION METHOD THEREFOR

NºPublicación: EP4063865A1 28/09/2022

Solicitante:

BEIJING JINWOFU BIOENGINEERING TECH CO LTD [CN]

Resumen de: EP4063865A1

The present discosure discloses a detection kit and a preparation method thereof and a detection method for novel coronavirus, and relates to the technical field of biomedicine, including antigen test strip; the antigen test strip includes a substrate, bibulous paper, immune nitrocellulose membrane, and immune microsphere pad; the immune microsphere pad, the immune nitrocellulose membrane and the bibulous paper are pasted on the substrate; the immune microsphere pad is coated with latex microsphere-labeled novel coronavirus SARS-CoV-2 monoclonal antibody 1; immune nitrocellulose membrane is provided with a test line coated with novel coronavirus SARS-CoV-2 monoclonal antibody 2 and a quality control line coated with goat anti-mouse IgG polyclonal antibody. The present disclosure uses latex particles as labeled tracer, and uses antigen-antibody reaction and lateral chromatography to detect and analyze targets, having advantages of convenience and swift, and is convenient to be widely carried out in grass-roots community hospitals and health service centers.

traducir

COMPOSITION, KIT, METHOD FOR DETECTING SARS-COV-2 AND USE THEREOF

NºPublicación: EP4063523A1 28/09/2022

Solicitante:

SANSURE BIOTECH INC [CN]

WO_2021243921_A1

Resumen de: EP4063523A1

A composition for detecting SARS-CoV-2 is provided; moreover, a kit including the composition, the use of the kit, and a method for detecting SARS-CoV-2 are also provided.

traducir

HUMAN NEUTRALIZING ANTIGEN SPECIFIC PROTEINS FOR SPIKE-RBD OF SARS-COV-2

NºPublicación: EP4063384A1 28/09/2022

Solicitante:

CEINGE BIOTECNOLOGIE AVANZATE SCARL [IT]

WO_2022200291_A2

Resumen de: EP4063384A1

The invention concerns antigen specific proteins, in particular antibodies of fragments thereof, specifically binding to RBD domain and interfering in the interaction of Spike protein with ACE2 receptor, said antigen specific proteins having neutralizing activity for SARS-CoV2 virus infection.

traducir

METHODS AND DEVICES DETECTING SARS-COV-2

Nº publicación: EP4061962A1 28/09/2022

Solicitante:

SARMAL INC [US]

CA_3159007_PA

Resumen de: WO2021102210A1

Provided herein are methods, systems and devices for detecting a nucleic acid sequences and/or pathogens; including detecting the presence of absence of a target-nucleic acid sequences, including SARS-COV2.

traducir

previousPage Página2 de 18 nextPage por página

punteroimgVolver